Potassium-Competitive Acid Blockers Market: Redefining Acid Suppression Therapy
The global Potassium-Competitive Acid Blockers (P-CABs) market is emerging as a transformative segment within the gastrointestinal therapeutics landscape. Long dominated by proton pump inhibitors (PPIs) and H2 receptor antagonists, the treatment of acid-related disorders is now entering a new phase driven by the superior pharmacological profile of P-CABs. These next-generation acid suppressants offer faster onset, sustained acid control, and more predictable efficacy, positioning them as strong alternatives to conventional therapies. As gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori infections continue to rise globally, healthcare systems are increasingly looking toward P-CABs to address unmet clinical needs and improve patient outcomes. Click Here to Download a Free Sample Report Understanding Potassium-Competitive Acid Blockers Potassium-competitive acid blockers work by reversibly inhibiting the gastric H⁺/K⁺-ATPase enzyme , commonly known as...